Physician profile
Mark S Romoff
NPI 1578543179
$3,094.20
in general payments reported to CMS, 2019-2025
25 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $267 · 2021: $101 · 2022: $697 · 2023: $608 · 2024: $498 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331 · Education: $51.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.41 |
| Education | $51.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $471.71 | 2019-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.62 | 2022-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $284.36 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $273.05 | 2022-2024 | |
| Abbvie INC. | $237.95 | 2021-2023 | Qulipta |
| Pfizer INC. | $169.69 | 2023-2025 | |
| Abbott Laboratories | $165.26 | 2023 | Proclaim, Freestyle Libre 3 |
| Opko Pharmaceuticals, LLC | $158.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $137.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $117.43 | 2023-2025 | |
| Lilly USA, LLC | $105.84 | 2020-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $100.41 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.61 | 2019-2022 | |
| Amarin Pharma, INC. | $58.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $58.24 | 2019-2024 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $53.68 | 2022 | |
| Exact Sciences Corporation | $50.01 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $46.37 | 2020-2024 | Rexulti |
| Mallinckrodt Hospital Products INC. | $34.93 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.72 | 2024 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $23.83 | 2022 | |
| Boston Scientific Corporation | $23.79 | 2020 | |
| Esperion Therapeutics, INC. | $23.38 | 2023 | Nexletol |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Vifor Pharma, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Romoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.